Ionis Pharmaceuticals (IONS) Common Equity (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Common Equity of $439.7 million for Q2 2026, down 30.39% year-over-year from $631.7 million in Q2 2025, and down 10.52% quarter-over-quarter from $491.4 million in Q1 2026.
Ionis Pharmaceuticals (IONS) Common Equity (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $439.7 million for Q2 2026.
- In Q2 2026, Common Equity fell 30.39% year-over-year to $439.7 million; the TTM figure through Jun 2026 stood at $439.7 million (down 30.39% YoY), while the FY2025 annual figure was $489.1 million, down 16.87% from the prior year.
- Common Equity for Q2 2026 stood at $439.7 million, down from $491.4 million in the prior quarter.
- The five-year high for Common Equity was $709.6 million in Q1 2022, with the low at $263.7 million in Q2 2024.
- The 5-year median for Common Equity is $490.3 million (2025), against an average of $504.2 million.
- The sharpest annual moves came in 2023 and 2025: Common Equity slumped 46.92% in 2023, then surged 139.56% in 2025.
- Ionis Pharmaceuticals' Common Equity stood at $572.9 million in 2022, then plunged by 32.5% to $386.7 million in 2023, then surged by 52.15% to $588.4 million in 2024, then declined by 16.87% to $489.1 million in 2025, then retreated by 10.09% to $439.7 million in 2026.
- Business Quant data shows IONS's Common Equity at $439.7 million in Q2 2026, $491.4 million in Q1 2026, and $489.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | 439.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 439.74 Mn |
| Mar 31, 2026 | 491.41 Mn |
| Dec 31, 2025 | 489.09 Mn |
| Sep 30, 2025 | 617.97 Mn |
| Jun 30, 2025 | 631.72 Mn |
| Mar 31, 2025 | 475.73 Mn |
| Dec 31, 2024 | 588.35 Mn |
| Sep 30, 2024 | 662.47 Mn |
| Jun 30, 2024 | 263.70 Mn |
| Mar 31, 2024 | 296.52 Mn |
| Dec 31, 2023 | 386.69 Mn |
| Sep 30, 2023 | 315.46 Mn |
| Jun 30, 2023 | 428.30 Mn |
| Mar 31, 2023 | 486.57 Mn |
| Dec 31, 2022 | 572.89 Mn |
| Sep 30, 2022 | 594.36 Mn |
| Jun 30, 2022 | 624.73 Mn |
| Mar 31, 2022 | 709.57 Mn |
| Dec 31, 2021 | 771.74 Mn |
| Sep 30, 2021 | 530.54 Mn |